The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Iteration of second-generation drug-eluting stents: the missing piece of evidence

EuroIntervention 2017;12:1927-1929. DOI: 10.4244/EIJV12I16A314

1. Polo Cardio-Toraco-Vascolare, Policlinico S. Orsola, Bologna, Italy;2. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, and Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy

Extraordinary claims require extraordinary evidence

Carl Sagan (1934-1996)

Iteration of second-generation drug-eluting stents (DES) utilising novel stent materials, designs and delivery systems, with enhanced biocompatible polymers or bioabsorbable polymers, and new antiproliferative agents, has significantly improved the outcomes of patients undergoing percutaneous coronary intervention compared with early-generation DES1. The availability of several new devices to treat coronary artery disease poses the question as to their relative safety and efficacy. In particular, establishing whether new DES with bioabsorbable polymers are superior, similar or inferior in terms of safety and efficacy compared with second-generation DES with permanent polymers remains ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified